News Conference News ACC 2025 ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a) L.A. McKeown April 10, 2025
News Conference News ACC 2025 EARLY TAVR: Delaying Valve Replacement Increases Risk of Poor Outcomes L.A. McKeown April 07, 2025
News Conference News ACC 2025 DETECT-AS: Alert System Increases AV Replacement in Eligible Patients Michael O'Riordan April 04, 2025
News Conference News ACC 2025 Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years L.A. McKeown March 30, 2025
News Conference News ACC 2025 More ALIGN-AR Data Bolster Potential for a Dedicated AR Device Yael L. Maxwell March 30, 2025
News Conference News ACC 2025 Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI Caitlin E. Cox March 30, 2025
News Conference News ACC 2025 Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection Michael O'Riordan March 30, 2025
News Conference News ACC 2024 Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6 Yael L. Maxwell April 08, 2024
Presentation ACC 2024 Self-Expanding Versus Balloon-Expandable TAVR in Patients with Aortic Stenosis and Small Aortic Annuli Presenter: Howard C. Herrmann April 07, 2024
News Conference News ACC 2024 SMART: Small Aortic Annuli May Fare Best With Self-Expandable Valve L.A. McKeown April 07, 2024
News Conference News ACC 2024 TAVI, SAVR Rates Roughly Equal for Patients Younger Than 65 in New England Yael L. Maxwell April 05, 2024
News Conference News ACC 2023 Self-Expanding TAVI Holds Up to Surgery Out to 3 Years in Low-Risk Patients Todd Neale March 05, 2023
News Conference News ACC 2022 ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI Todd Neale April 05, 2022
News Conference News ACC 2022 Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years Michael O'Riordan April 04, 2022
News Conference News ACC 2022 APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study Michael O'Riordan April 03, 2022
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Conference News ACC 2021 ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI Yael L. Maxwell May 15, 2021
News Conference News ACC 2020 Early Data Support TAVR in Bicuspid Valves, but Questions Remain Michael O'Riordan March 29, 2020
News Conference News ACC 2020 PARTNER 3: TAVR Now Noninferior to Surgery at 2 Years in Low-Risk Patients Yael L. Maxwell March 29, 2020
News Conference News ACC 2020 UK TAVI: Real-world TAVR and SAVR Have Similar 1-Year Mortality L.A. McKeown March 29, 2020